Skip to main content

Haleon plc

corporate_fare Company Profile

Haleon plc

HLN·NYSE·Industrial Applications And Services·CIK 0001900304

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Aquafresh, and Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also provides various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Otrivine, Theraflu, and Flonase brands for respiratory issues; anti-inflammatory and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was founded in 1715 and is headquartered in Weybridge, the United Kingdom.

Haleon plc (NYSE:HLN) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 10 items for HLN at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-07-30, rated 7/10. Across its 10 most recent items scored 7 or higher, the top rating is 8/10, with 3 rated 8 or above. Recent SEC coverage for HLN spans 6-K, 20-F.

Recent high-impact activity:

  • Haleon H1 2026: Organic Revenue +2.6%, Adjusted EPS +12%, Buyback Nearly Complete
  • Haleon H1 2026: Organic Growth 2.6%, Adjusted EPS +12%, £457M Buyback Executed
  • Haleon Continues Share Buyback, Cancelling Nearly 7 Million Shares
  • Haleon plc Buys Back $60.3 Million in Shares, Continuing Program Near 52-Week Lows
  • Haleon Reports £54M ($68.6M) Share Buyback, Cancelling 16.6M Shares

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
£11.03B GBP
Net Income
£1.68B GBP
Diluted EPS
£0.18 GBP
Op. Cash Flow
£2.63B GBP
Free Cash Flow
£2.31B GBP
Gross Profit
£7.08B GBP
Operating Income
£2.41B GBP
Cash & Equivalents
£1.32B GBP
Total Debt
£7.77B GBP
Debt / Equity
0.47×
Net Margin
15.2%
Shares Outstanding
8.95B sh
Source: 20-F · filed 2026-03-13 · accession 0001104659-26-027443

Short Interest & Short Volume

1.47 days to cover

FINRA reported short interest of 21,803,768 shares in HLN as of the September 15, 2026 settlement, a 41.9% increase from the prior period — about 1.5 days to cover at its recent average daily volume. On October 2, 2026, 26.7% of HLN volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)21,803,768 shares as of September 15, 2026
Change vs prior period▲ 41.9%
Days to cover1.47 at avg daily volume of 14,850,693
Daily short volume (FINRA facilities)26.7% of 7,734,997 shares on October 2, 2026
5-day average short volume32.0%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for HLN, detected from its recent SEC filings · based on capital-structure filings through 2026-08-13.

1 recent capital raise

Shelf Registration Filed · Use of Proceeds

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Insider Transactions

HLN files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

Browse all tickers starting with H →
$8.81 +0.01% today
52-week range · as of 2026-07-30 $8.65 – $11.28
Market cap
$38.08B
Volume
22.4M (1.3× avg)
3-mo avg 17.9M
Live data · 2026-10-03 10:38 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed HLN - Latest Insights

HLN
Jul 30, 2026, 12:14 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $10.03
Real-time Price: $8.81 info
Change: -$1.22 (-12%) info
Market Cap: $38.083B info
HLN
Jul 30, 2026, 7:00 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $9.97
Real-time Price: $8.81 info
Change: -$1.16 (-12%) info
Market Cap: $38.083B info
HLN
Jun 29, 2026, 6:22 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $9.26
Real-time Price: $8.81 info
Change: -$0.4545 (-5%) info
Market Cap: $38.083B info
HLN
Jun 22, 2026, 6:42 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $8.84
Real-time Price: $8.81 info
Change: -$0.0345 (-0.39%) info
Market Cap: $38.083B info
HLN
Jun 08, 2026, 3:59 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $8.91
Real-time Price: $8.81 info
Change: -$0.0995 (-1%) info
Market Cap: $38.083B info
HLN
Jun 01, 2026, 6:16 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $9.02
Real-time Price: $8.81 info
Change: -$0.2145 (-2%) info
Market Cap: $38.083B info
HLN
Mar 13, 2026, 9:59 AM EDT
Filing Type: 20-F
Importance Score:
8
Price at Filing: $10.15
Real-time Price: $8.81 info
Change: -$1.34 (-13%) info
Market Cap: $38.083B info
HLN
Mar 12, 2026, 10:17 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $10.18
Real-time Price: $8.81 info
Change: -$1.37 (-14%) info
Market Cap: $38.083B info
HLN
Feb 25, 2026, 6:07 AM EST
Filing Type: 6-K
Importance Score:
8
Price at Filing: $10.57
Real-time Price: $8.81 info
Change: -$1.76 (-17%) info
Market Cap: $38.083B info
HLN
Jan 08, 2026, 9:58 AM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $10.01
Real-time Price: $8.81 info
Change: -$1.20 (-12%) info
Market Cap: $38.083B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets